CAS Medical gets two US patents for Fore-Sight cerebral oximeter:
This article was originally published in Clinica
Executive Summary
CAS Medical Systems has gained two US patents for technology used in its noninvasive Fore-Sight cerebral oximeter, which is scheduled for commercial release in late 2006. The product uses the firm's optically-based near infrared spectroscopy technology to monitor absolute levels of oxygen saturation in the brain. This absolute value, displayed on the monitor and updated every few seconds, provides clinicians with an immediate, clear indication of a patient's cerebral oxygen saturation status, said the Branford, Connecticut firm. Cerebral tissue oxygen saturation values are important because lack of oxygen supply to brain tissue is one of the leading causes of brain injuries that occur in many surgical and clinical situations.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.